

Question

Can we identify those patients with high risk TNBC that DO NOT need 1 year of pembrolizumab in high risk early TNBC?

Study design

Standard neoadjuvant
chemotherapy +
pembrolizumab for
high-risk TNBC

S
Y
R
G
E
R
Y

R

No adjuvant pembrolizumab

Adjuvant pembrolizumab (27 weeks)

Stratification for pathological complete response at surgery

Expected impact

- Optimize adjuvant treatment duration in high-risk early TNBC
- Spare young women with TNBC from toxicity related to 1 year of pembrolizumab
- Spare society and EU states from a costly treatment

Financial Impact

- Each year 400000 new cases of breast cancer with an estimated 50000 new cases of TNBC are diagnosed in the 28 European Union countries (EU-28) ¹
- Pembrolizumab cost 9K Euros/dose, 162K Euros for 1 year treatment for one patient ²,
- Under a conservative assumption that 10000 high risk early TNBC patients / year need pembrolizumab and that in at least half of them (5000 patients) 6 months can be safely given instead of 1 year:

**total expected cost savings could be 405,000,000 Euros/
year for the EU-28**

¹Dafni U et al Breast Care 2019

² <https://www.keytruda.com/financial-support/> accessed 02/12/21